March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
A Topical Ocular Toxicity Study of Dexamethasone Sodium Phosphate Formulations Administered with Visulex-p in Rabbits
Author Affiliations & Notes
  • Kongnara Papangkorn
    Aciont Inc, Salt Lake City, Utah
    Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah
  • Donald Mix
    Aciont Inc, Salt Lake City, Utah
  • Charlotte Butler
    Aciont Inc, Salt Lake City, Utah
  • David J. Knauss
    Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah
  • John W. Higuchi
    Aciont Inc, Salt Lake City, Utah
  • Balbir Brar
    Aciont Inc, Salt Lake City, Utah
  • William I. Higuchi
    Aciont Inc, Salt Lake City, Utah
    Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah
  • Footnotes
    Commercial Relationships  Kongnara Papangkorn, Aciont Inc (E); Donald Mix, Aciont Inc (E); Charlotte Butler, Aciont Inc (E); David J. Knauss, Aciont Inc (F); John W. Higuchi, Aciont Inc (E); Balbir Brar, Aciont Inc (E); William I. Higuchi, Aciont Inc (E)
  • Footnotes
    Support  NEI Grant 2R44EY014772-02A1
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kongnara Papangkorn, Donald Mix, Charlotte Butler, David J. Knauss, John W. Higuchi, Balbir Brar, William I. Higuchi; A Topical Ocular Toxicity Study of Dexamethasone Sodium Phosphate Formulations Administered with Visulex-p in Rabbits. Invest. Ophthalmol. Vis. Sci. 2012;53(14):478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To assess the ocular tolerability of Visulex-p (Vp) containing dexamethasone sodium phosphate (DSP) following daily dosing for 7 days and weekly dosing for 12 weeks in New Zealand white rabbits.

 
Methods:
 

Twenty-one 5-6 months old rabbits were assigned to seven groups according to Table 1. Vp loaded with 250 ul of the test formulation was applied to the right eye. Vp was then removed at the end of the application. The ocular examinations, with an indirect ophthalmoscope, modified McDonald-Shadduck scoring, and fluorescein staining were completed at pre-, post-, and at selected time-points post-dose. The body weight was recorded at baseline and during the study. After the final observation, animals were sacrificed and the eyes were collected for histological examination for any signs of inflammation, including edema/congestion (conjunctiva, ciliary body, cornea), inflammatory cell infiltration (conjunctiva, cornea, anterior chamber, trabecular meshwork, iris, ciliary body), and neovascularization of cornea.

 
Results:
 

Ocular findings are summarized in Table 1. Conjunctival injection and chemosis were observed right after dosing in all groups, with severity increasing with dosing concentrations. Resolution was observed within the 1-7 days after each application. At doses of 8% and higher, there was a longer time to resolution with continued weekly treatment. Weight loss occurred with 15% and 25% DSP. No corneal damage was seen at any of the dose groups. No ocular findings were observed in histopathology.

 
Conclusions:
 

Vp containing 4% and 8% DSP formulation is well tolerated in rabbit for 7 days of daily dosing and over a 3 month period of weekly dosing. Although Vp containing 8% and 15% DSP formulation treatments showed an accumulation of irritation scores over 3 months, there were no signs of irreversible ocular tissue damage in any of the rabbits.  

 
Keywords: ocular irritancy/toxicity testing • drug toxicity/drug effects • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×